Adenocarcinoma

A 43-year-old female was diagnosed with an adenocarcinoma of the ascending colon and received 6-months of adjuvant chemotherapy. After 5 years of completion of adjuvant chemotherapy, the disease relap… (full text at CIViC)

PMID 19661358 · Palmirotta et al., 2009 · Open in CIViC

The Medical Research Council (MRC) COIN trial consisted of patients with histologically confirmed adenocarcinoma of the colon or rectum, inoperable metastatic or locoregional measurable disease, and w… (full text at CIViC)

PMID 21641636 · Maughan et al., 2011 · Open in CIViC

A gene fusion between exon 11 of LMNA and exon 10 of NTRK1 was observed in a patient with metastatic colorectal cancer after therapy with first-line FOLFOX, second-line FOLFIRI/cetuximab, and third-li… (full text at CIViC)

PMID 26546295 · Russo et al., 2016 · Open in CIViC

A gene fusion between exon 10 of NTRK1 and exon 11 of the LMNA genes was observed in a patient with metastatic colorectal cancer after therapy with first-line FOLFOX, second-line FOLFIRI/cetuximab, an… (full text at CIViC)

PMID 26546295 · Russo et al., 2016 · Open in CIViC

In a retrospective LUAD cohort treated with PD-1 plus CTLA-4 blockade (n = 59; LRP1B-MT n = 15, LRP1B-WT n = 44), LRP1B-mutated tumors showed significantly longer PFS (log-rank p = 0.0016), along with… (full text at CIViC)

PMID 37057124 · He et al., 2023 · Open in CIViC

Xu et al. retrospectively analyzed paired pre- and post-EGFR tyrosine kinase inhibitor samples from 3,873 patients with EGFR-mutant lung adenocarcinoma and identified an acquired LRRC71::NTRK1 fusion … (full text at CIViC)

PMID 31372039 · Xu et al., 2019 · Open in CIViC

10 biliary tract carcinoma cell lines were sorted based on their gemcitabine sensitivity. MAGEH1 protein expression was negatively correlated with sensitivity. In a clinical validation cohort, MAGEH p… (full text at CIViC)

PMID 20088962 · Ojima et al., 2010 · Open in CIViC

In a study of 6,024 lung adenocarcinomas, 36 conferred MEK1 mutations whereby 64% (n=23) were K57N and 19% (n=7) were Q56P. Median overall survival of MEK1-mutated tumors was not significantly differe… (full text at CIViC)

PMID 25351745 · Arcila et al., 2015 · Open in CIViC

Mutational profiling of 207 lung adenocarcinomas identified in 2 of with activating mutation in exon 2 of MEK1 (K57N) in the nonkinase portion of the kinase. Neither of these two tumors harbored known… (full text at CIViC)

PMID 18632602 · Marks et al., 2008 · Open in CIViC

Case report of a 51-year old patient with recurrent low-grade serous ovarian cancer. Selumetinib treatment in a phase-II trial led to a complete and durable response > 5 years. Sequencing (MSK-IMPACT … (full text at CIViC)

PMID 26324360 · Grisham et al., 2015 · Open in CIViC

In this case report, a 66-year old woman with pancreatic ductal adenocarcinoma was treated with trametinib for a BRAF in-frame-deletion and TP53 mutation and achieved an initial partial response for c… (full text at CIViC)

PMID 29903880 · Aguirre et al., 2018 · Open in CIViC

In this case report, a 66-year old woman with pancreatic ductal adenocarcinoma was treated with trametinib for a BRAF in-frame-deletion and TP53 mutation and achieved an initial partial response for c… (full text at CIViC)

PMID 29903880 · Aguirre et al., 2018 · Open in CIViC

Two patients diagnosed with oncocytic thyroid carcinoma (hurthle cell thyroid carcinoma) were evaluated for MEN1 mutations. One tumor showed 592-end deletion of MEN1 and the other showed a 521 frames… (full text at CIViC)

PMID 25625803 · Kasaian et al., 2015 · Open in CIViC

Cabozantinib's effect on cell proliferation was studied in a variety of cell lines. In two gastric adenocarcinoma cell lines with MET amplification (SNU-5 and Hs746T) were the most sensitive to caboz… (full text at CIViC)

PMID 21926191 · Yakes et al., 2011 · Open in CIViC

In an evaluation of a patient with crizotinib-sensitive lung adenocarcinoma, an MET-Amplification was identified using CGP. The patient attained a reduction in the target lesions by 38.7%, and the pa… (full text at CIViC)

PMID 25922291 · Le et al., 2015 · Open in CIViC

A 76-year old male (non-smoker) presented with stage IV lung adenocarcinoma with metastatic disease in the lung and thoracic vertebra (T2). Next-generation sequencing revealed a MET exon 14 skipping m… (full text at CIViC)

PMID 27257131 · Liu et al., 2016 · Open in CIViC

An 82-year old male (smoker: 60 pack-years) was diagnosed with lung adenocarcinoma. Initial tumor tissue testing revealed MET amplification (GCN = 13.5). The patient was enrolled in a phase 2 trial an… (full text at CIViC)

PMID 36248327 · Choi et al., 2022 · Open in CIViC

A patient diagnosed with lung adenocarcinoma had cells cultured to create patient-derived cell lines. Such cells exhibited MET amplification and showed overexpression of MYC. Capmatinib was administer… (full text at CIViC)

PMID 36248327 · Choi et al., 2022 · Open in CIViC

Lung adenocarcinoma cell lines (H3122: EML4-ALK E13:A20, HCC78: SLC34A2-ROS1, H1993: MET amplification, and H596: MET exon 14 skipping) with putative crizotinib-sensitive genotypes were analyzed with … (full text at CIViC)

PMID 26791794 · Jorge et al., 2015 · Open in CIViC

This study contained 230 patients presenting with untreated lung adenocarcinoma. Tumor and matched normal material were analyzed via whole-exome sequencing. It was shown that ~62% of samples contained… (full text at CIViC)

PMID 25079552 · 2014, Nature · Open in CIViC

69 patients with lung adenocarcinoma from Beth Israel Deaconess Medical Center had their cancers submitted for genomic profiling to identify crizotinib-sensitive genomic events. There were 7 cases tha… (full text at CIViC)

PMID 26791794 · Jorge et al., 2015 · Open in CIViC

In a lung adenocarcinoma patient harboring MET D1028H mutation, a partial response to crizotinib treatment was reported with continued response for at least 6 months. Prior to crizotinib treatment, th… (full text at CIViC)

PMID 25898962 · Waqar et al., 2015 · Open in CIViC

In a lung adenocarcinoma patient harboring a MET D1010H mutation, stable disease to crizotinib monotherapy was reported. The patient was treated with crizotinib for 4 months; treatment was ongoing at … (full text at CIViC)

PMID 27343443 · Schrock et al., 2016 · Open in CIViC

In a lung adenocarcinoma patient with a MET D1010_splice mutation, a partial response to crizotinib treatment was reported with a 45.1% decrease in tumor measurement by RECIST v1.1. The patient experi… (full text at CIViC)

PMID 26791794 · Jorge et al., 2015 · Open in CIViC

In a lung adenocarcinoma patient harboring a MET D1010Y mutation, a partial response to crizotinib monotherapy was reported. The patient was treated with crizotinib for 7 months; treatment was ongoing… (full text at CIViC)

PMID 27343443 · Schrock et al., 2016 · Open in CIViC

A 77-year-old Caucasian woman (previous smoker) was diagnosed with stage IV adenocarcinoma with pleural disease. Initial genetic testing showed wild-type EGFR and ALK. She received six cycles of carbo… (full text at CIViC)

PMID 30762593 · Wang et al., 2019 · Open in CIViC

A patient with MET c.3028+1G>T mutation (METex14) had partial response (tumor reduction of 61%) after 13 months capmatinib. MET gene copy number was four, MET FISH 13.8 copy number, and IHC 3+.

PMID 25971938 · Frampton et al., 2015 · Open in CIViC

A 71-year old woman (non-smoker) was diagnosed with poorly differentiated lung adenocarcinoma following immunohistochemistry of tumor cells and biopsy staining. High PD-L1 expression was also confirme… (full text at CIViC)

PMID 30600919 · Baba et al., 2019 · Open in CIViC